Website
N/ATelephone
61.2.9209.4037
Address
4 Cornwallis Street National Innovation Centre Eveleigh, New South Wales (NSW) 2015
Description
Clarity Pharmaceuticals Ltd. is a clinical stage radiopharmaceutical company. It engages in research and development and clinical stage evaluation of its portfolio of novel radiopharmaceuticals products. The company was founded by Matthew Harris on April 8, 2010 and is headquartered in Eveleigh, Australia.
Market Cap
PE
EV/EBITDA
DIV Yield
Franking
Ex Dividend Date (est.)
52 weeks range
Low 0.68 - 1.5
Trade Value (12mth)
AU$69,374.00
1 week
14.62%
1 month
31.86%
YTD
52.04%
1 year
56.02%
All time high
1.71
EPS 3 yr Growth
248.500%
EBITDA Margin
N/A
Operating Cashflow
-$27m
Free Cash Flow Return
-34.10%
ROIC
-30.50%
Interest Coverage
N/A
Quick Ratio
10.20
Shares on Issue (Fully Dilluted)
260m
HALO Sector
Healthcare
Next Company Report Date
21-Aug-24
Ex Dividend Date (est.)
N/A
Next Dividend Pay Date (est.)
N/A
Reporting Currency
AUD
Short Sell (% of issue)
0.00
Date | Announcements |
---|---|
31 October 23 |
Quarterly Activities/Appendix 4C Cash Flow Report
×
Quarterly Activities/Appendix 4C Cash Flow Report |
31 October 22 |
Quarterly Activities/Appendix 4C Cash Flow Report
×
Quarterly Activities/Appendix 4C Cash Flow Report |
31 May 22 |
Clarity adds innovative nanobody IP
×
Clarity adds innovative nanobody IP |
31 May 22 |
Change of Director's Interest Notice - Rob Thomas
×
Change of Director's Interest Notice - Rob Thomas |
31 July 23 |
Quarterly Activities/Appendix 4C Cash Flow Report
×
Quarterly Activities/Appendix 4C Cash Flow Report |
31 January 23 |
Quarterly Activities/Appendix 4C Cash Flow Report
×
Quarterly Activities/Appendix 4C Cash Flow Report |
31 January 22 |
Quarterly Activities/Appendix 4C Cash Flow Report
×
Quarterly Activities/Appendix 4C Cash Flow Report |
30 September 22 |
Date of AGM
×
Date of AGM |
30 November 23 |
undetectable PSA level with Cu-67 SAR-bisPSMA
×
undetectable PSA level with Cu-67 SAR-bisPSMA |
30 November 23 |
Phase III CLARIFY trial in prostate cancer commences
×
Phase III CLARIFY trial in prostate cancer commences |
30 November 23 |
Ceasing to be a substantial holder
×
Ceasing to be a substantial holder |
30 January 23 |
Notification regarding unquoted securities - CU6
×
Notification regarding unquoted securities - CU6 |
30 December 21 |
Application for quotation of securities - CU6
×
Application for quotation of securities - CU6 |
30 December 21 |
Becoming a substantial holder
×
Becoming a substantial holder |
29 September 23 |
Annual Report to shareholders
×
Annual Report to shareholders |
29 September 23 |
Corporate Governance Statement
×
Corporate Governance Statement |
29 September 21 |
Notice of Annual General Meeting
×
Notice of Annual General Meeting |
29 November 23 |
SECuRE theranostic prostate cancer trial progresses
×
SECuRE theranostic prostate cancer trial progresses |
29 June 22 |
Leading Australian cancer expert joins Clarity SAB
×
Leading Australian cancer expert joins Clarity SAB |
29 June 22 |
Application for quotation of securities - CU6
×
Application for quotation of securities - CU6 |
29 December 21 |
Application for quotation of securities - CU6
×
Application for quotation of securities - CU6 |
29 April 22 |
Quarterly Activities/Appendix 4C Cash Flow Report
×
Quarterly Activities/Appendix 4C Cash Flow Report |
28 October 22 |
Corporate Presentation - Wilsons Drug and Device Conference
×
Corporate Presentation - Wilsons Drug and Device Conference |
28 November 23 |
Application for quotation of securities - CU6
×
Application for quotation of securities - CU6 |
28 November 23 |
Application for quotation of securities - CU6
×
Application for quotation of securities - CU6 |
28 November 23 |
Cleansing Notice
×
Cleansing Notice |
28 March 23 |
Application for quotation of securities - CU6
×
Application for quotation of securities - CU6 |
28 March 23 |
Cleansing Notice
×
Cleansing Notice |
Load More
Load Less
Historical data
Forecasted data
Load More
Load Less
Historical data
Forecasted data
Load More
Load Less
Historical data
Forecasted data
Load More
Load Less
Percent of Issue
Value ($M)
Prior Change
7 Day Change
1 Month Change
3 Month Change
Access data on short interest, stock performance, and potential short-selling candidates across various markets to make informed decisions and optimize your trading strategies.
Unlock true investor intelligence
Research, trade and manage global markets from one place with HALO Global. It’s trading - the way you want it.
Get the latest insights and hot tips delivered right to your inbox
HALO Technologies Pty Ltd ABN 54 623 830 866 is a Corporate Authorised Representative No 1261916 of Macrovue Pty Ltd ABN 98 600 022 679 AFSL 484264. Macrovue Pty Ltd is a wholly owned subsidiary of HALO Technologies Pty Ltd.